利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.022 秒)

    Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay
    3.
    发明公开
    Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay 失效
    用于制备在单克隆/多克隆夹心免疫​​测定法中为游离和复合分析物提供等摩尔响应的单克隆抗体的方法

    公开(公告)号：EP0789032A3

    公开(公告)日：1997-08-20

    申请号：EP97100856.0

    申请日：1997-01-21

    申请人： Bayer Corporation

    发明人： Zhou, Zeqi ,  Armstrong E. Glenn Jr. ,  Yeung, Kwok K.

    IPC分类号： C07K16/40 ,  C07K16/38 ,  G01N33/573 ,  G01N33/53

    CPC分类号： G01N33/57434 ,  C07K16/40

    摘要： A method for preparing a monoclonal antibody which, when used in a monoclonal/polyclonal antibody sandwich immunoassay method for measuring an analyte which can exist in both free and binding protein complexed forms in a biological test sample, provides an equimolar response to the free and complexed forms of the analyte. The monoclonal antibody is selected to have the properties of (i) upon binding to the analyte, rendering the analyte substantially incapable of binding with antibodies that can bind the free form, but not the complexed form, of the analyte, and (ii) binding substantially equivalently with free and complexed analyte. The method is particularly useful in the measurement of prostate-specific antigen (PSA) in blood, serum or plasma.

    摘要翻译： 用于制备单克隆抗体的方法，当用于测量在生物测试样品中以游离和结合蛋白复合形式存在的分析物的单克隆/多克隆抗体夹心免疫测定方法时，提供对游离和复合的等摩尔响应 分析物的形式。 选择单克隆抗体以具有以下性质：（i）在与分析物结合后，使分析物基本上不能与能够结合分析物的游离形式而不是复合形式的抗体结合，和（ii）结合 基本上等同于游离和复合的分析物。 该方法在测量血液，血清或血浆中的前列腺特异性抗原（PSA）中特别有用。

    Recombinant prostate-specific antigen and its use as an immunoassay calibrator
    4.
    发明公开
    Recombinant prostate-specific antigen and its use as an immunoassay calibrator 失效
    Rekombinantes前列腺特异性抗原和抗体Verwendung als Immunoassay-Kalibrator

    公开(公告)号：EP0725139A2

    公开(公告)日：1996-08-07

    申请号：EP96101304.2

    申请日：1996-01-31

    申请人： Bayer Corporation

    发明人： Yeung, Kwok K. ,  Barnett, Thomas R. ,  Ng, Phillip C.

    IPC分类号： C12N15/57 ,  C12N9/64 ,  G01N33/573

    CPC分类号： C12N9/6445

    摘要： Recombinant PSA (rPSA), including immunologically cross-reactive fragments, and its use as an immunoassay calibrator. rPSA is free-form PSA, uncomplexed with proteolytic inhibitors, and shows immunoreactivity in commercial PSA tests.

    摘要翻译： 重组PSA（rPSA），包括免疫交叉反应性片段，以及其作为免疫分析校准物的用途。 rPSA是游离形式的PSA，不与蛋白水解抑制剂复合，并且在商业PSA测试中显示出免疫反应性。

    Diagnosis and monitoring of colon cancer patients by measurement of NCA 50/90 in blood
    5.
    发明公开
    Diagnosis and monitoring of colon cancer patients by measurement of NCA 50/90 in blood 失效
    诊断和通过在血液中NCA九十○分之五十○的测量监测的结肠癌患者。

    公开(公告)号：EP0628820A2

    公开(公告)日：1994-12-14

    申请号：EP94106221.8

    申请日：1994-04-21

    申请人： Bayer Corporation

    发明人： Allard, William Jeffrey ,  Yeung, Kwok K.

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57446

    摘要： A method for aiding in the diagnosis of, and monitoring the progression or course of, colon cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g., serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of colon cancer in a symptomatic patient. The course of colon cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

    摘要翻译： 一种用于在帮助诊断，并通过测量血液样品中的NCA90分之50的量监测患者体内的进展或当然，结肠癌症的方法，E. G.，血清样品，从患者获得。 NCA九十分之五十明显比NCA九十分之五十在正常群体中的平均量更高的量的单一样品中的测量是结肠癌的有症状患者的指示。 结肠癌的过程因此可以通过随着时间的推移进行一系列特定的免疫测定在NCA90分之50的血液样品中的水平确定性矿的变化来监测。 在血液NCA 50/90水平随时间的增加是表明鉴于降低血液NCA 50/90加班水平的病情不断恶化表明在改进条件。

    Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay
    7.
    发明公开
    Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay 失效
    一种用于在单克隆/多克隆夹心免疫​​制备的单克隆抗体的equimolärenResponz针对游离和复合测试样品的方法

    公开(公告)号：EP0789032A2

    公开(公告)日：1997-08-13

    申请号：EP97100856.0

    申请日：1997-01-21

    申请人： Bayer Corporation

    发明人： Zhou, Zeqi ,  Armstrong E. Glenn Jr. ,  Yeung, Kwok K.

    IPC分类号： C07K16/40 ,  C07K16/38 ,  G01N33/573 ,  G01N33/53

    CPC分类号： G01N33/57434 ,  C07K16/40

    摘要： A method for preparing a monoclonal antibody which, when used in a monoclonal/polyclonal antibody sandwich immunoassay method for measuring an analyte which can exist in both free and binding protein complexed forms in a biological test sample, provides an equimolar response to the free and complexed forms of the analyte. The monoclonal antibody is selected to have the properties of (i) upon binding to the analyte, rendering the analyte substantially incapable of binding with antibodies that can bind the free form, but not the complexed form, of the analyte, and (ii) binding substantially equivalently with free and complexed analyte. The method is particularly useful in the measurement of prostate-specific antigen (PSA) in blood, serum or plasma.

    摘要翻译： 一种用于制备单克隆抗体的方法，该方法，当在单克隆/多克隆抗体夹心免疫测定方法，用于同时可在自由和生物测试样品中结合蛋白复合的形式，提供在对游离和复合等摩尔响应存在的分析物的测定中使用 分析物的形式。 单克隆抗体被选择在结合于分析物，使该分析物基本上不能与抗体结合也能够结合游离形式为具有（i）所述的特性，而不是复合形式，分析物，和（ii）的结合 实质上等同自由和络合分析。 该方法是在血液，血清或血浆前列腺特异性抗原（PSA）的测量是特别有用的。

    Specific determination of NCA 90 glycoform in the blood of cancer patients
    8.
    发明公开
    Specific determination of NCA 90 glycoform in the blood of cancer patients 失效
    Spezifische Bestimmung von NCA 90 Glykoprotein im Blut eines Krebspatienten

    公开(公告)号：EP0747705A1

    公开(公告)日：1996-12-11

    申请号：EP96108409.2

    申请日：1996-05-28

    申请人： Bayer Corporation

    发明人： Very, Donald L. ,  Yeung, Kwok K. ,  Allard, William Jeffrey

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57488

    摘要： It has been found that although both glycoforms of the cancer marker NCA 50/90 are expressed in normal tissue, only the 90 kDa glycoform is secreted into the bloodstream. An improved method is therefore provided for aiding in the diagnosis of, and monitoring the progression or course of cancer, particularly breast, colon, and lung cancer, and leukemia, in a patient by measuring the amount of NCA 90 specifically in a blood sample, e.g., serum sample, obtained from the patient.

    摘要翻译： 已经发现，虽然癌症标志物NCA 50/90的两个糖型都在正常组织中表达，但只有90kDa糖型分泌到血液中。 因此，提供了一种改进的方法，用于通过测量血液样品中的NCA 90的量来帮助诊断和监测患者中癌症，特别是乳腺癌，结肠癌和肺癌以及白血病的进展或过程， 例如，从患者获得的血清样品。

    Diagnosis and monitoring of lung cancer patients by measurement of NCA 50/90 in blood
    9.
    发明公开
    Diagnosis and monitoring of lung cancer patients by measurement of NCA 50/90 in blood 失效
    诊断和通过在血液中NCA九十○分之五十○的测量监测的肺癌患者。

    公开(公告)号：EP0621480A3

    公开(公告)日：1995-09-06

    申请号：EP94106222.6

    申请日：1994-04-21

    申请人： Bayer Corporation

    发明人： Allard, William Jeffrey ,  Yeung, Kwok K.

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57423

    摘要： A method for aiding in the diagnosis of, and monitoring the progression of, lung cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g., serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of lung cancer in the patient. The progression of lung cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.